Last €58.10 EUR
Change Today +1.77 / 3.14%
Volume 10.1K
ZEG On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 11:51 AM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (ZEG) Snapshot

Open
€56.47
Previous Close
€56.33
Day High
€58.42
Day Low
€56.16
52 Week High
05/19/14 - €64.20
52 Week Low
10/10/13 - €36.61
Market Cap
73.4B
Average Volume 10 Days
3.9K
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
08/13/14
P/E TM
--
Dividend
€3.00
Dividend Yield
3.93%
Current Stock Chart for ASTRAZENECA PLC (ZEG)

astrazeneca plc (ZEG) Details

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc.; FibroGen, Inc.; Roche Holding AG; Qiagen N.V.; and Illumina, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

51,500 Employees
Last Reported Date: 03/20/14
Founded in 1992

astrazeneca plc (ZEG) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.0M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 259.0K GBP
Compensation as of Fiscal Year 2013.

astrazeneca plc (ZEG) Key Developments

AstraZeneca and Illumina Inc. Partner to Develop NGS Panel for Companion Diagnostics

AstraZeneca has entered into a collaboration with Illumina Inc. to develop its next generation sequencing, or NGS, platform for companion diagnostic tests applicable across AstraZeneca's oncology portfolio. In the first instance, AstraZeneca intends to apply Illumina's technology to a novel companion diagnostic test in pivotal studies for one of its investigational oncology compounds. Illumina's NGS technology allows rapid sequencing of multiple genes in a much faster and cheaper way than traditional DNA sequencing methods. Under the collaboration, it will be used to screen a panel of several gene sequences, scanning for all possible genetic variants - known and unknown - rather than specified mutations from a single tumour sample. The comprehensive information obtained from sequencing full genes will be used to predict which patients will respond to certain treatments, and will go through appropriate regulation. Doctors are increasingly using companion diagnostic tests as an essential part of personalised healthcare to help them understand the causes of disease at a molecular level.

AstraZeneca Announces Positive Results from CLEAR1, CLEAR2 and CRYSTAL

AstraZeneca has announced positive results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor, or SURI, as a combination therapy for the treatment of patients with symptomatic gout. Lesinurad is an investigational agent that inhibits the URAT1 transporter, increasing uric acid excretion and thereby lowering serum uric acid (sUA). CLEAR1 and CLEAR2 studied lesinurad (200mg and 400mg once daily) in combination with the xanthine oxidase (XO) inhibitor allopurinol, in symptomatic gout patients not achieving target sUA levels on their current allopurinol dose. CRYSTAL studied lesinurad (200mg and 400mg once daily) in combination with the XO inhibitor febuxostat (80mg once daily) in gout patients with tophi (visible nodules of uric acid crystals that are deposited in joints and skin). In CRYSTAL, the three most commonly reported adverse events for patients receiving lesinurad in combination with febuxostat were nasopharyngitis, arthralgia and upper respiratory tract infection. The incidence of renal-related adverse events (including serious events) and incidence of kidney stones with lesinurad 200mg plus XO inhibitor was comparable to placebo plus XO inhibitor. The incidence of renal-related adverse events and kidney stones was higher with lesinurad 400mg plus XO inhibitor. A full assessment of the safety and tolerability findings of all three studies is ongoing.

Pfizer Reportedly To Resume Talks To Acquire AstraZeneca

Reports regarding plans of Pfizer Inc. (NYSE:PFE) to take over AstraZeneca PLC (LSE:AZN) has caused political ructions on both sides of the Atlantic - without an agreed deal on the table, reported CNBC. CNBC added that with the expiration of a three-month period during which Pfizer must stay away from AstraZeneca, under U.K. takeover law, speculation that the maker of Viagra may eventually seal this deal has risen. Under U.K. takeover regulations, AZ management can now re-engage with Pfizer (but not the other way round). Pfizer has one chance to approach AstraZeneca with a new bid in the next three months, but it must be done in private under U.K. takeover laws, and may mean the company paying above the odds for its smaller rival. Pfizer and AstraZeneca spokespeople declined to comment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEG:GR €58.10 EUR +1.77

ZEG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $55.28 USD -0.32
Amgen Inc $139.38 USD +0.69
Biogen Idec Inc $343.04 USD +1.80
Bristol-Myers Squibb Co $50.65 USD +0.11
Novo Nordisk A/S kr259.00 DKK +1.00
View Industry Companies
 

Industry Analysis

ZEG

Industry Average

Valuation ZEG Industry Range
Price/Earnings 47.2x
Price/Sales 3.7x
Price/Book 4.3x
Price/Cash Flow 47.3x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.